Biosynthesis of Zinc Oxide Nanoparticles Using Catharanthus roseus Leaves and Their Therapeutic Response in Breast Cancer (MDA-MB-231) Cells

Zinc oxide nanomaterials are effective in cancer treatments, including the destruction of tumor cells with minimal damage to healthy cells. In the study, the biologically synthesized (Catharanthus roseus) zinc oxide nanomaterials with a broad 18-30 nm range were produced and the toxicity of zinc oxide nanomaterials was checked in vitro in the human breast cancer line MDA-MB-231. Inverse relation of the percentage of viable cells to the concentration of zinc oxide nanomaterials at increasing molar levels was assessed. The cytotoxicity analysis used in the MTT test shows the substantial viable MDA-MB-231-cells despite the increased concentration of exposure to zinc oxide nanomaterials. Reduction in the ratio of viable MDA-MB-231 cells after being exposed to zinc oxide nanomaterials was compared to untreated cancerous cells. The present approach to biosynthesis is quick, inexpensive, eco-friendly, and high-rise stable nanomaterials of zinc oxide with substantial cancer potential. This is the first study that reports molar concentrations as an anticancer agent for breast cancer and potential clinical uses for synthesized zinc oxide nanomaterials.

Automated summary

Zinc oxide nanomaterials, synthesized biologically, demonstrate potential as effective and environmentally friendly anticancer agents, showing a reduction in viable breast cancer cells in vitro. This study marks a significant step in utilizing molar concentrations of synthesized zinc oxide nanomaterials for potential clinical use in breast cancer treatment.